logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
S

Seth A. Wander

Harvard University
H指数:35
被引数:5,287

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy

III期postMONARCH试验中，阿贝西利联合氟维司群与安慰剂联合氟维司群治疗既往接受过CDK4/6抑制剂联合内分泌治疗后进展的HR+、HER2-晚期乳腺癌的总体生存率

Annals of Oncology
IF65.4
2026-10-240
OA
Kevin Kalinsky; Seth A. Wander; Erika Hamilton; Stephanie L. Graff; Rinath Jeselsohn; Kyong Hwa Park; Umut Demirci; Miguel Martin; Rachel M. Layman; Sara A. Hurvitz; Sarah Sammons; Peter A. Kaufman; Elizabeth Ravenberg; Sasha Amdur; Lacey M. Litchfield; Giampaolo Bianchini
Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2– metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial

伊帕西替布联合内分泌疗法和CDK4/6抑制剂在HR+/HER2–转移性乳腺癌中的安全性和抗肿瘤活性（TAKTIC）：一项单中心、开放标签、1b期临床试验

The Lancet Oncology
IF0
2026-04-270
PRE
Seth A Wander; Maxwell R Lloyd; Jennifer C Keenan; Elizabeth C Scott; Andrzej Niemierko; Laura M Spring; Geoffrey G Fell; Jennifer Shin; Steven J Isakoff; Beverly Moy; Lianne Ryan; Sarah Padden; Elizabeth Fisher; Amber Newton; Karleen R Habin; Elene T Viscosi-Spieler; Lauren Scarpetti; Andreas Varkaris; Leif W Ellisen; Taronish Dubash
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer

NF1基因改变与CDK4/6抑制剂耐药在激素受体阳性转移性乳腺癌中的从临床到基础研究的转化分析

eBioMedicine
IF10.8
2025-06-270
PRE
Maxwell R. Lloyd; Rosario Chica-Parrado; Caroline M. Weipert; Todd C. Knepper; Emily L. Podany; Fabiana Napolitano; Dan Ye; Chang-Ching Lin; Yasuaki Uemoto; Jiemin Liao; Claire Wegrzyn; Christine M. Walko; Lianne Y. Ryan; Jennifer C. Keenan; Arielle J. Medford; Shiyuan A. Liu; Gerburg M. Wulf; Katherine K. Clifton; Cynthia X. Ma; Hyo S. Han; Nicole Zhang; Leif W. Ellisen; Aditya Bardia; Carlos L. Arteaga; Ariella B. Hanker; Seth A. Wander
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)
NPJ BREAST CANCER
IF7.6
2025-01-070
OA
Spring, Laura M.; Scarpetti, Lauren; Medford, Arielle J.; Niemierko, Andrzej; Comander, Amy; Mulvey, Therese; Schnipper, Lowell; Isakoff, Steven J.; Moy, Beverly; Wander, Seth A.; Shin, Jennifer; Ephrem, Zanta; Laposta, Anneke R.; Denault, Elyssa; Abraham, Elizabeth; Calistro, Gayle; Kalashnikova, Ekaterina; Rodriguez, Angel; Liu, Minetta C.; Aleshin, Alexey; Peppercorn, Jeffrey; Ellisen, Leif W.; Bardia, Aditya
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment

CDK4/CDK6抑制剂在激素受体阳性乳腺癌治疗中的敏感性和耐药机制

DRUG RESISTANCE UPDATES
IF21.7
2024-09-014
OAAI
Glaviano, Antonino; Wander, Seth A.; Baird, Richard D.; Yap, Kenneth C. -H.; Lam, Hiu Yan; Toi, Masakazu; Carbone, Daniela; Geoerger, Birgit; Serra, Violeta; Jones, Robert H.; Ngeow, Joanne; Toska, Eneda; Stebbing, Justin; Crasta, Karen; Finn, Richard S.; Diana, Patrizia; Vuina, Karla; de Bruin, Robertus A. M.; Surana, Uttam; Bardia, Aditya; Kumar, Alan Prem
Interim analysis (IA) of the giredestrant (G) plus samuraciclib (SAMURA) arm in MORPHEUS breast cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)

MORPHEUS乳腺癌（BC）研究中，giredestrant（G）联合samuraciclib（SAMURA）组的期中分析（IA）：一项在雌激素受体阳性（ER+）、HER2阴性、局部晚期/转移性乳腺癌（LA/mBC）患者中评估G治疗方案组合的I/II期研究。

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Oliveira, M.; Gion Cortes, M.; Jung, K. H.; Bermejo, B.; Hurvitz, S. A.; Sadeghi, S.; Wander, S.; Im, S-A.; Gal-Yam, E.; Zhu, J.; Schwab, R.; Ngo, H.; Collier, A.; Cannon, M.; Cahuzac, C.; Moreno, P. D. Perez; Mcintosh, S.; Saavedra Serrano, C.; Sonnenblick, A.
Abemaciclib plus fulvestrant for HR+, HER2-advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Subgroup analyses from the phase III postMONARCH trial

Abemaciclib联合fulvestrant用于既往接受过CDK4/6抑制剂联合内分泌治疗进展后的HR+、HER2-晚期乳腺癌：postMONARCH III期试验的亚组分析

ANNALS OF ONCOLOGY
IF65.4
2024-09-011
PRE
Bianchini, G.; Jimenez, M. Martin; Graff, S.; Jeselsohn, R.; Wander, S.; Layman, R.; Hurvitz, S. A.; Hamilton, E. P.; Sammons, S.; Kaufman, P.; Knoderer, H.; Nguyen, B.; Zhou, Y.; Ravenberg, E.; Litchfield, L.; Kalinsky, K.
A bedside-to-bench translational analysis demonstrates that NF1 alterations promote CDK4/6 inhibitor (CDK4/6i) resistance in hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Lloyd, Maxwell; Chica-Parrado, M. Rosario; Knepper, Todd; Lin, Chang-Ching; Podany, Emily; Walko, Christine; Napolitano, Fabiana; Weipert, Caroline; Liao, Jiemin; Medford, Arielle; Ryan, Lianne; Keenan, Jennifer; Zhang, Nicole; Liu, Shiyuan; Wulf, Gerburg; Clifton, Katherine; Ma, Cynthia; Han, Hyo; Ellisen, Leif; Bardia, Aditya; Arteaga, Carlos; Hanker, Ariella; Wander, Seth

研究方向

暂未获取到该数据
A
Aditya Bardia
H 指数:86论文数:1,147被引数:3.8万
B
Beverly Moy
H 指数:57论文数:429被引数:1.3万
L
Laura M. Spring
H 指数:36论文数:469被引数:6,759
L
Leif W. Ellisen
H 指数:66论文数:464被引数:2.4万
S
Steven J. Isakoff
H 指数:60论文数:449被引数:2.5万
J
Joyce M. Slingerland
H 指数:64论文数:215被引数:1.9万
D
Dekuang Zhao
H 指数:18论文数:108被引数:1,644
A
Arielle J. Medford
H 指数:13论文数:146被引数:834
M
Maxwell R. Lloyd
H 指数:15论文数:109被引数:2,413
D
Dejan Juric
H 指数:59论文数:732被引数:2.0万